Perampanel: A Selective AMPA Antagonist for Treating Seizures-Reference-Cited by-同舟云学术

Perampanel: A Selective AMPA Antagonist for Treating Seizures

Published:2013-11 Issue:6 Volume:13 Page:269-272
ISSN:1535-7597
Container-title:Epilepsy Currents
language:en
Short-container-title:Epilepsy Curr

Author:

Krauss Gregory L.¹

Affiliation:

1. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD

Abstract

Perampanel is a selective, noncompetitive AMPA receptor antagonist that has recently been approved for treating localization-related epilepsy. This article reviews the pharmacology, clinical development, efficacy, and safety/tolerability of perampanel.

Publisher

SAGE Publications

Subject

Neurology (clinical)

Link

http://journals.sagepub.com/doi/pdf/10.5698/1535-7597-13.6.269

Reference13 articles.

1. A crossover, add-on trial of talampanel in patients with refractory partial seizures

2. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

3. Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist

4. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WRAPPER study: Real‐world effectiveness and tolerability of adjunctive perampanel for people with drug–resistant epilepsy in Hong Kong;Epilepsia Open;2023-12-26

2. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study;Epilepsy & Behavior;2022-11

3. Perampanel-Induced Psychosis in a Young Woman: A Case Report;Clinical Neuropharmacology;2021-11

4. Clinical effects and outcomes of perampanel overdoses reported to U.S. poison centers;Clinical Toxicology;2021-07-19

5. Insomnia is less prevalent and less severe, independent of depressive symptoms, in patients with epilepsy treated with perampanel as an adjuvant;Epilepsy & Behavior;2020-11